Investigating the Role of Sodium-glucose Cotransporter-2 Inhibitors in Slowing Down the Diabetic Kidney Disease Progression: A Meta-analysis of Randomized Control Trials

Abstract

Background: The one of most common and severe complications is diabetic kidney disease, which leads to in the long term. However, there are many recent developments in medical therapy, especially when we use inhibitors SGLT2, which always gives us the best outcome in improving patient compliance and reducing the higher risk of mortality which is associated with the long-run consequences of diabetic metabolic control. Purpose: This comprehensive systematic review delves into the efficacy of SGLT2 inhibitors which have capacity to slow down the progression rate of diabetes kidney disorder. Methods: The eligibility criteria were set up following the PRISMA guidelines' which are recommended 'population, intervention, comparison, outcome, and study (PICOS) design ' framework. Various digital databases, such as ClinicalTrials.gov, PubMed, Google Scholar, Cochrane, Medline, Embase, and others, were meticulously scanned to pinpoint relevant studies. A search strategy, crafted in line with the inclusion and exclusion criteria, was utilized to acquire the most pertinent studies. Results: For this study, we selected twelve studies. Upon systematic scrutiny, it was revealed that a majority of these studies, precisely eight out of twelve (67%), showcased the effectiveness of SGLT2 inhibitors in diminishing kidney indicators like eGFR and UACR among diverse populations. Conversely, a lack of significant impact on primary endpoints was noted in four out of twelve studies (33.3%). Conclusion: In the treatment of diabetic kidney disease (DKD), SGLT2 inhibitors present a hopeful option, showing considerable promise in slowing down the advancement of the illness and improving kidney function.